These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6296035)

  • 1. Comparative pharmacokinetics of ceftizoxime and other third-generation cephalosporins in humans.
    Quintiliani R; Nightingale CH
    J Antimicrob Chemother; 1982 Nov; 10 Suppl C():99-104. PubMed ID: 6296035
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of the new cephalosporins.
    Brogard JM; Comte F
    Antibiot Chemother (1971); 1982; 31():145-210. PubMed ID: 6277241
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative pharmacokinetics of moxalactam, cefoperazone, and cefotaxime in normal volunteers.
    Standiford HC; Drusano GL; McNamee WB; Tatem B; Ryan PA; Schimpff SC
    Rev Infect Dis; 1982; 4 Suppl():S585-94. PubMed ID: 6296967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam.
    Kemmerich B; Lode H; Belmega G; Jendroschek T; Borner K; Koeppe P
    Antimicrob Agents Chemother; 1983 Mar; 23(3):429-34. PubMed ID: 6303213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and bacteriological efficacy of cefoperazone, ceftriaxone, and moxalactam in experimental Streptococcus pneumoniae and Haemophilus influenzae meningitis.
    McCracken GH; Nelson JD; Grimm L
    Antimicrob Agents Chemother; 1982 Feb; 21(2):262-7. PubMed ID: 6280599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibacteroides and beta-lactamase inhibitory activities of moxalactam.
    Fu KP; Neu HC
    J Antimicrob Chemother; 1981 Oct; 8(4):337-41. PubMed ID: 6271727
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetic properties of the newer cephalosporins. A valid basis for drug selection?
    Noble JT; Barza M
    Drugs; 1985 Sep; 30(3):175-81. PubMed ID: 3899596
    [No Abstract]   [Full Text] [Related]  

  • 8. The activity of five cephalosporins against Bacteroides fragilis.
    Ryan RW; Kwasnik I; Tilton RC
    Ann Clin Lab Sci; 1982; 12(1):32-4. PubMed ID: 6279014
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.
    Lüthy R; Blaser J; Bonetti A; Simmen H; Wise R; Siegenthaler W
    Rev Infect Dis; 1982; 4 Suppl():S581-4. PubMed ID: 6296966
    [No Abstract]   [Full Text] [Related]  

  • 10. Activity and specific beta-lactamase susceptibility of cefoperazone and moxalactam. Comparison with other cephalosporins.
    Mouton RP; Bongaerts GP; van Gestel M; Bruggeman-Ogle KM
    Chemotherapy; 1981; 27(5):318-24. PubMed ID: 6455258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Third-generation cephalosporins: a critical evaluation.
    Barriere SL; Flaherty JF
    Clin Pharm; 1984; 3(4):351-73. PubMed ID: 6432420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and bacteriologic efficacy of moxalactam, cefotaxime, cefoperazone, and rocephin in experimental bacterial meningitis.
    Schaad UB; McCracken GH; Loock CA; Thomas ML
    J Infect Dis; 1981 Feb; 143(2):156-63. PubMed ID: 6260870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative tissue and extravascular fluid concentrations of ceftizoxime.
    Gerding DN; Peterson LR
    J Antimicrob Chemother; 1982 Nov; 10 Suppl C():105-16. PubMed ID: 6295995
    [No Abstract]   [Full Text] [Related]  

  • 14. The cephalosporin antibiotic agents--III. Third-generation cephalosporins.
    Marsh TD
    Infect Control; 1985 Feb; 6(2):78-83. PubMed ID: 3882594
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels.
    Wise R; Baker S; Livingston R
    Antimicrob Agents Chemother; 1980 Sep; 18(3):369-71. PubMed ID: 6252833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of third generation cephalosporins combined with amikacin against Pseudomonas aeruginosa.
    Rodríguez JR; Hernández NI; Ramírez-Ronda CH; Nevárez M
    Bol Asoc Med P R; 1985 Jun; 77(6):242-4. PubMed ID: 3931655
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.
    Lüthy R; Blaser J; Bonetti A; Simmen H; Wise R; Siegenthaler W
    Antimicrob Agents Chemother; 1981 Nov; 20(5):567-75. PubMed ID: 6275776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The in vitro activity, human pharmacology, and clinical effectiveness of new beta-lactam antibiotics.
    Neu HC
    Annu Rev Pharmacol Toxicol; 1982; 22():599-642. PubMed ID: 6282190
    [No Abstract]   [Full Text] [Related]  

  • 19. Diffusibility of the newer cephalosporins into human interstitial fluids.
    Tan JS; Salstrom SJ; File TM
    Am J Med; 1984 Oct; 77(4C):33-6. PubMed ID: 6093516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro antimicrobial activity of ceftizoxime.
    Schell RF; LeFrock JL; Smith BR; Francisco M
    Chemotherapy; 1983; 29(6):408-14. PubMed ID: 6317295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.